Evercore ISI Group Downgrades Edwards Lifesciences to In-Line, Lowers Price Target to $77
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Vijay Kumar has downgraded Edwards Lifesciences (NYSE:EW) from Outperform to In-Line and reduced the price target from $80 to $77.
January 04, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Edwards Lifesciences was downgraded by Evercore ISI Group from Outperform to In-Line, and the price target was lowered from $80 to $77.
Downgrades by analysts can lead to a negative perception among investors, potentially causing a short-term decline in the stock price. The reduction in the price target further supports the expectation of a downward movement.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100